Multiple Sclerosis (MS) Drug Market

MarketWatch  Apr 20  Comment 
Atara Biotherapeutics Inc. shares climbed in the extended session Thursday after the biotech drug developer reported positive results from an early stage clinical trial of its multiple sclerosis drug. Atara shares rose 8.7% to $20.55 after hours....
Forbes  Apr 20  Comment 
Diagnosed with multiple sclerosis in 2000, he set out to find the safest, most effective form of medicinal cannabis for treating his disease and others, and bring that product to the masses.
New York Times  Apr 5  Comment 
Bryan Bickell returned to the N.H.L. after five months, and is believed to be the third person to play in the N.H.L. with multiple sclerosis.
DailyFinance  Apr 3  Comment 
Filed under: News, Discovery - Health, Science & Tech The root for the word vitamin is "vita" from the Latin word meaning "life." Now researchers are finding that vitamin D can help the lives of people suffering with multiple sclerosis by...
MedPage Today  Apr 1  Comment 
(MedPage Today) -- Also: first drug OK'd for progressive multiple sclerosis
The Hindu Business Line  Mar 31  Comment 
THERAPEUTIC ADVANCE The United States Food and Drug Administration has approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive...
New York Times  Mar 29  Comment 
The drug, Ocrevus by Genentech, can also be used to treat patients with the more common form of the disease.  Mar 28  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration approved OCREVUS or ocrelizumab as the first and only medicine for both relapsing and primary progressive forms...  Mar 15  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - The U.S. Food and Drug Administration said it approved Ocrevus or ocrelizumab to treat adult patients with relapsing forms of multiple sclerosis or MS and primary progressive multiple sclerosis or PPMS. Ocrevus is...
Benzinga  Mar 2  Comment 
Perrigo Company plc Ordinary Shares (NYSE: PRGO) announced on Monday it would divest its rights to the royalty stream from the global net sales of multiple sclerosis drug Tysabri in favor of privately-held Royalty Pharma. Tysabri is a drug...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki